Leis, J.F., Stepan, D.E., Curtin, P.T., et al. (2001) Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL. Blood, 98, 140.

has been cited by the following article:

• TITLE: Philadelphie chromosome—Positive de novo acute myeloid leukemia. Isolated meningeal relapse in a patient treated with imatinib mesylate

  AUTHORS: I. Ben Amor, S. Hdiji Mseddi, O. Kassar, S. Hdiji Mnif, Ines Jdidi, M. Mdhaffar, L. Kammoun, H. Bellaaj, A. Saad, M. Elloumi

  KEYWORDS: Acute Myeloid Leukemia; Philadelphie Chromosome; Meningeal Relapse

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.2, May 24, 2013

  ABSTRACT: Acute myeloid leukemia philadelphie positive (Ph+ AML) is a rare aggressive acute leukemia with poor prognosis. We report a patient with ph positive AML (FAB5), the transcript bcr/abl was not performed at diagnosis. She achieved complete remission after conventional induction chemotherapy. The consolidation therapy was based on Imatinib only due to infectious complications. She was in complete hematologic and cytogenetic remission for 19 months, and after she exhibited an isolated meningeal relapse. A second remission was achieved with intrathecal chemotherapy and cranial irradiation. Imatinib was switched to second generation Tyrosine kinase Inhibitor which had better diffusion into cerebrospinal fluid. She is in complete hematologic, cytogenetic and meningeal remission after 14 months of treatment. Imatinib monotherapy affords insufficient protection from CNS relapse. Second generation Tyrosine kinase Inhibitor seems to have better efficiency. Ph+ AML with monoblastic differentiation should be considered, like Ph+ ALL, at high risk of meningeal leukemia and should receive central nervous system prophylaxis.